Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
Ava KwongVivian Yvonne ShinCecilia Y S HoChun Hang AuThomas P SlavinJeffrey N WeitzelTsun-Leung ChanEdmond S K MaPublished in: BMC cancer (2020)
In view of the high lifetime risk of malignancy, identification of patients with germline TP53 mutations are important for clinicians to aid in accurate risk assessment and offer surveillance for patients and their families.